We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Cardinal (CAH) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Cardinal Health (CAH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.42 per share, reflecting an increase of 16.4% compared to the same period last year. Revenues are forecasted to be $65.61 billion, representing a year-over-year increase of 9.1%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Cardinal metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Revenue- Pharmaceutical and Specialty Solutions' will reach $60.99 billion. The estimate points to a change of +10.1% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Other' will reach $1.80 billion. The estimate indicates a change of +12% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Medical Products and Distribution' at $3.26 billion. The estimate points to a change of +2% from the year-ago quarter.
Analysts expect 'Segment profit- Pharmaceutical and Specialty Solutions' to come in at $628.03 million. The estimate is in contrast to the year-ago figure of $535.00 million.
The collective assessment of analysts points to an estimated 'Segment profit- Other' of $181.15 million. The estimate compares to the year-ago value of $160.00 million.
Analysts forecast 'Segment profit- Global Medical Products and Distribution' to reach $42.02 million. The estimate compares to the year-ago value of $70.00 million.
Over the past month, Cardinal shares have recorded returns of +0.9% versus the Zacks S&P 500 composite's +3.3% change. Based on its Zacks Rank #2 (Buy), CAH will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Curious about Cardinal (CAH) Q4 Performance? Explore Wall Street Estimates for Key Metrics
In its upcoming report, Cardinal Health (CAH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.42 per share, reflecting an increase of 16.4% compared to the same period last year. Revenues are forecasted to be $65.61 billion, representing a year-over-year increase of 9.1%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Cardinal metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Revenue- Pharmaceutical and Specialty Solutions' will reach $60.99 billion. The estimate points to a change of +10.1% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Other' will reach $1.80 billion. The estimate indicates a change of +12% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Medical Products and Distribution' at $3.26 billion. The estimate points to a change of +2% from the year-ago quarter.
Analysts expect 'Segment profit- Pharmaceutical and Specialty Solutions' to come in at $628.03 million. The estimate is in contrast to the year-ago figure of $535.00 million.
The collective assessment of analysts points to an estimated 'Segment profit- Other' of $181.15 million. The estimate compares to the year-ago value of $160.00 million.
Analysts forecast 'Segment profit- Global Medical Products and Distribution' to reach $42.02 million. The estimate compares to the year-ago value of $70.00 million.
View all Key Company Metrics for Cardinal here>>>Over the past month, Cardinal shares have recorded returns of +0.9% versus the Zacks S&P 500 composite's +3.3% change. Based on its Zacks Rank #2 (Buy), CAH will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .